MDxHealth SA

As of June 30, 2026, MDxHealth SA carries a market capitalization of 21.09M, placing it among publicly traded companies globally. Its enterprise value stands at 107.73M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

MDxHealth SA's next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, MDxHealth SA has 51.36M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.39, and the price-to-book ratio stands at -0.69.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.97 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 107.73M versus a market cap of 21.09M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, MDxHealth SA maintains a current ratio of 1.15, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -348.13, indicating conservative leverage, while an interest coverage ratio of -0.51 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -14.57, reflecting losses generated across the asset base. The company generates approximately 149,986.26 in revenue per employee across its workforce of 364.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.05 indicates how many times MDxHealth SA sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, MDxHealth SA's stock has declined approximately 95.50% over the past 52 weeks. The 50-day moving average sits at 0.62, while the 200-day moving average is 1.62.

Over the twelve months ended June 30, 2026, MDxHealth SA generated 54.60M in revenue and converted that into -20.40M in net income, yielding earnings per share of -0.35. EBITDA reached -7.62M, while operating income came in at -12.40M.

As of June 30, 2026, MDxHealth SA holds 19.21M in cash and equivalents against 105.85M in total debt, resulting in a net debt position of 77.20M. Total book value stands at -30.40M, with working capital of 5.63M providing operational flexibility.

MDxHealth SA produced -7.34M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -401,000.00 in capital expenditures, free cash flow totaled -7.74M - equivalent to -0.15 per share.

Over the twelve months ended June 30, 2026, MDxHealth SA posted a gross margin of 63.20, reflecting its pricing power and cost economics. The operating margin of -22.72 and net profit margin of -37.36 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, MDxHealth SA paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -36.06: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -26.91, meaning MDxHealth SA raised more capital through share issuance and new debt than it returned via dividends and buybacks.

MDxHealth SA's most recent stock split took place on November 14, 2023 with a 10:1 split ratio.

As of June 30, 2026, MDxHealth SA has an Altman Z-Score of -10.12, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.